peptic%20ulcer%20disease
PEPTIC ULCER DISEASE
Peptic ulcer disease is the presence of ulceration in the stomach and proximal duodenum commonly and in the lower esophagus, distal duodenum or jejunum infrequently. It is characterized by mucosal damage secondary to pepsin and gastric acid secretion.
It is the principal cause of upper gastrointestinal hemorrhage.
Appropriate therapy depends on the cause of peptic ulcer disease.

Introduction

  • Peptic ulcer disease (PUD) is characterized by mucosal damage secondary to pepsin and gastric acid secretion
  • It is the principal cause of upper gastrointestinal (UGI) hemorrhage
  • Most commonly occurs in the stomach and proximal duodenum; infrequently, in the lower esophagus, distal duodenum or jejunum
  • Giant ulcer with size of 3 cm is an atypical type of PUD that is now rarely encountered
  • Dyspepsia is a nonspecific term indicating discomfort in the upper abdomen
  • Refractory PUD is considered in patents with ulcer that failed to heal after 8-12 weeks of therapy

Signs and Symptoms

Clinical Features
  • Epigastric pain is the most common symptom of peptic ulcer disease (PUD) but occurs only in minority of patients
    • Pain of duodenal ulcer usually occurs 2-3 hours after a meal, improves with food or antacid, and sometimes awakens patient at night
    • Pain of gastric ulcer is more commonly worsened by food intake and occurs shortly after meals
      • May be associated with weight loss due to fear of food intake
  • Other symptoms include indigestion, vomiting, loss of appetite, inability to tolerate fatty foods, heartburn
    • Nausea and vomiting are commonly experienced by patients with prepyloric or pyloric channel ulcers

Alarm Symptoms

  • Hematemesis, melena, or anemia may suggest bleeding
  • Vomiting and early satiety may be due to obstruction
  • Anorexia or weight loss may suggest cancer
  • Upper abdominal pain radiating to the back that persists may be due to penetration
  • Spreading upper abdominal pain that is severe may suggest perforation

Risk Factors

Risk Factors
  • In 70% of cases, 25- to 64-year old patients are affected
  • 48% and 50% of cases are secondary to Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) respectively
    • Some evidence states that H pylori infection may be food or water borne and may spread from person to person
    • In patients with a bleeding ulcer, it is recommended to test for and treat H pylori
    • NSAIDs inhibit the formation of prostaglandins and their protective effect on the gastric mucosa (ie stimulates mucus and bicarbonate secretion, epithelial cell proliferation, and increase of mucosal blood flow)
      • Patients who are on long-term NSAIDs have an annual risk of life-threatening ulcer-related complication of 1-4%
    • H pylori plus NSAID use increases the risk and intensity of NSAID-related mucosal damage
  • Other causes may include use of steroids, bisphosphonates, potassium chloride or chemotherapeutic agents, presence of acid-hypersecretory states (eg Zollinger-Ellison syndrome), cancer or stress [eg multiorgan failure, ventilator support, extensive burns (Curling’s ulcer) or head injury (Cushing’s ulcer)], lifestyle factors, genetic factors
  • In patients with NSAID-related GI complications, additional contributing factors include history of complicated GI event, age, concomitant use of anticoagulants, corticosteroids, other NSAIDs including low-dose Aspirin, high-dose therapy, chronic debilitating disorders
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 6 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
3 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
3 days ago
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.